Sanofi’s eyes approval after MS therapy slows disease progression by 31%

cafead

Administrator
Staff member
  • cafead   Sep 22, 2024 at 09:42: PM
via After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS patients.

article source
 

<